Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Popat on the DREAMM-1 Trial in Relapsed/Refractory Multiple Myeloma

November 28th 2019

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses results from the phase I, dose-expansion DREAMM-1 trial in relapsed/refractory multiple myeloma.

Dr. Giralt on Current Standard of Care for Newly Diagnosed Multiple Myeloma

November 27th 2019

Sergio A. Giralt, MD, discusses the current frontline standard of care for patients with multiple myeloma.

Dr. Braunstein on the Bone Marrow Microenvironment in Multiple Myeloma

November 27th 2019

Marc J. Braunstein, MD, PhD, discusses challenges pertaining to the bone marrow microenvironment in multiple myeloma.

Sequencing Challenges Emerge in Myeloma After Recent Approvals

November 26th 2019

Sham Mailankody, MBBS, discusses ongoing research and recent advances in relapsed/refractory multiple myeloma.

Dr. Shinohara on Stereotactic Body Radiotherapy to Treat Prostate Cancer

November 26th 2019

Eric Shinohara, MD, MSCI, discusses the emergence of stereotactic body radiotherapy to treat patients with prostate cancer.

Dr. Chari on Quadruplet Regimens in Transplant-Eligible Multiple Myeloma

November 26th 2019

Ajai Chari, MD, discusses the implementing quadruplet-regimens in transplant-eligible multiple myeloma.

Dr. Stadtmauer on BCMA-Targeting in Multiple Myeloma

November 26th 2019

Edward A. Stadtmauer, MD, discusses what makes BCMA a unique target in multiple myeloma.

Frontline Standard in Myeloma Continues to Evolve

November 25th 2019

Sergio A. Giralt, MD, discusses the changing frontline treatment setting in multiple myeloma, how to determine transplant eligibility, and the utility of testing for minimal residual disease negativity.

Dr. Mailankody on MRD-Negative Status in Multiple Myeloma

November 23rd 2019

Sham Mailankody, MBBS, discusses minimal residual disease negativity in multiple myeloma.

Dr. Chari on Transplant Eligibility in Multiple Myeloma

November 21st 2019

Ajai Chari, MD, discusses transplant eligibility in multiple myeloma.

Dr. Garfall on Quadruplet Regimen in Multiple Myeloma

November 20th 2019

Alfred L. Garfall, MD, provides insight on the FDA approval of daratumumab added to bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Frontline Daratumumab Triplet Approved in EU for Transplant-Ineligible Myeloma

November 20th 2019

The European Commission has approved the triplet regimen of daratumumab with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Dr. Braunstein on Reclassifying Ultra High-Risk Smoldering Multiple Myeloma

November 20th 2019

Marc J. Braunstein, MD, PhD, discusses the ultra–high-risk patient population in smoldering multiple myeloma.

Dr. Lonial on Treatments in Heavily Pretreated Multiple Myeloma

November 16th 2019

Sagar Lonial, MD, FACP, discusses treatments for patients with heavily pretreated multiple myeloma.

Dr. Giralt on Evaluating MRD in Multiple Myeloma

November 15th 2019

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses methods of evaluating measurable residual disease (MRD) in multiple myeloma.

Dr. Nooka on Treatment Options for Transplant-Eligible and -Ineligible Multiple Myeloma

November 14th 2019

Ajay K. Nooka, MD, MPH, FACP, discusses current options for transplant-eligible and -ineligible patients with multiple myeloma.

Talking Tumors: Filling Data Gaps in Multiple Myeloma

November 14th 2019

We sat down with Ajai Chari, MD, and Sundar Jagannath, MD, both of Mount Sinai Hospital, to provide insight on controversial, but critical, questions regarding the merits of quadruplet versus triplet therapy in the newly diagnosed setting, the optimal maintenance approach in high-risk patients, and the data in support of and against initiating treatment in patients with smoldering multiple myeloma.

New Myeloma Guidelines Reflect Advances in Imaging, Explosion of Treatment Options

November 13th 2019

Imaging approaches and technologies have advanced dramatically since the last such guidance was developed a decade ago, driving earlier and more effective detection and treatment.

Dr. Borello on Treating Indolent Versus Aggressive Relapsed Multiple Myeloma

November 12th 2019

Ivan M. Borrello, MD, discusses treatment for patients with indolent versus aggressive relapsed multiple myeloma.

Dr. Lonial on Treating Early Relapse in Multiple Myeloma

November 12th 2019

Sagar Lonial, MD, FACP, discusses the management of patients with relapsed multiple myeloma.